Literature DB >> 23845811

Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle.

Melisa R Anggraeni1, Natalie K Connors, Yang Wu, Yap P Chuan, Linda H L Lua, Anton P J Middelberg.   

Abstract

Biomolecular engineering enables synthesis of improved proteins through synergistic fusion of modules from unrelated biomolecules. Modularization of peptide antigen from an unrelated pathogen for presentation on a modular virus-like particle (VLP) represents a new and promising approach to synthesize safe and efficacious vaccines. Addressing a key knowledge gap in modular VLP engineering, this study investigates the underlying fundamentals affecting the ability of induced antibodies to recognize the native pathogen. Specifically, this quality of immune response is correlated to the peptide antigen module structure. We modularized a helical peptide antigen element, helix 190 (H190) from the influenza hemagglutinin (HA) receptor binding region, for presentation on murine polyomavirus VLP, using two strategies aimed to promote H190 helicity on the VLP. In the first strategy, H190 was flanked by GCN4 structure-promoting elements within the antigen module; in the second, dual H190 copies were arrayed as tandem repeats in the module. Molecular dynamics simulation predicted that tandem repeat arraying would minimize secondary structural deviation of modularized H190 from its native conformation. In vivo testing supported this finding, showing that although both modularization strategies conferred high H190-specific immunogenicity, tandem repeat arraying of H190 led to a strikingly higher immune response quality, as measured by ability to generate antibodies recognizing a recombinant HA domain and split influenza virion. These findings provide new insights into the rational engineering of VLP vaccines, and could ultimately enable safe and efficacious vaccine design as an alternative to conventional approaches necessitating pathogen cultivation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomolecular engineering; Influenza; Modular; Receptor; VLP; Virus-like particle

Mesh:

Substances:

Year:  2013        PMID: 23845811     DOI: 10.1016/j.vaccine.2013.06.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Insert engineering and solubility screening improves recovery of virus-like particle subunits displaying hydrophobic epitopes.

Authors:  R S Abidin; L H L Lua; A P J Middelberg; F Sainsbury
Journal:  Protein Sci       Date:  2015-10-07       Impact factor: 6.725

2.  Assembly and Purification of Polyomavirus-Like Particles from Plants.

Authors:  Emeline V B Catrice; Frank Sainsbury
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

Review 3.  Platform technologies for modern vaccine manufacturing.

Authors:  Hayley K Charlton Hume; Linda H L Lua
Journal:  Vaccine       Date:  2017-03-25       Impact factor: 3.641

4.  An integrated and continuous downstream process for microbial virus-like particle vaccine biomanufacture.

Authors:  Lukas Gerstweiler; Jagan Billakanti; Jingxiu Bi; Anton P J Middelberg
Journal:  Biotechnol Bioeng       Date:  2022-05-10       Impact factor: 4.395

Review 5.  Subviral particle as vaccine and vaccine platform.

Authors:  Ming Tan; Xi Jiang
Journal:  Curr Opin Virol       Date:  2014-03-21       Impact factor: 7.090

6.  Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations.

Authors:  Lin Zhang; Ronghong Tang; Shu Bai; Natalie K Connors; Linda H L Lua; Yap P Chuan; Anton P J Middelberg; Yan Sun
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

Review 7.  Synthetic biology for bioengineering virus-like particle vaccines.

Authors:  Hayley K Charlton Hume; João Vidigal; Manuel J T Carrondo; Anton P J Middelberg; António Roldão; Linda H L Lua
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.